The thing buried in the article is that it would depend on the drug being approved as a twice-annual vaccine regiment, and assuming that there would be at least

The thing buried in the article is that it would depend on the drug being approved as a twice-annual vaccine regiment, and assuming that there would be at least 60 million people who participate in such a regiment. It's currently only approved as a niche treatment, and they may be hundreds of millions of dollars in medical trials away from it being approved from such a case.